PMID- 17309148
OWN - NLM
STAT- MEDLINE
DCOM- 20070327
LR  - 20220317
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 11
IP  - 3
DP  - 2006 Jul-Sep
TI  - Mammalian target of rapamycin is a promising target for novel therapeutic 
      strategy against cancer.
PG  - 267-76
AB  - Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the 
      cellular phosphatidylinositol 3-kinase (P13K) pathway. The P13K/Akt signaling 
      pathway plays a critical role in regulating basic cellular functions such as 
      control of transcription and translation. mTOR is a downstream mediator of 
      P13K/Akt and, as a result of its position, it has a central role in controlling 
      cellular growth and division. Previous reports demonstrated that rapamycin, which 
      inhibits mTOR activity, sensitizes certain resistant cancer cells to 
      chemotherapeutic agents. These facts have made mTOR to be viewed as an important 
      target for anti-cancer therapeutics development. Evidence suggests that the 
      rapamycin derivatives CCI-779 and RAD001 could induce G1-S cell cycle delay and 
      eventually apoptosis, depending on inner cellular characteristics of tumor cells. 
      At present, CCI-779 and RAD001 are being evaluated in cancer clinical trials. 
      From recent studies, these drugs appear to have a safe toxicity profile with skin 
      rashes and mucositis being prominent and dose-limiting. In this review we discuss 
      about the principal mechanisms of mTOR action and the current place of mTOR 
      inhibitors as novel therapeutic agents against cancer.
FAU - Bjelogrlic, S K
AU  - Bjelogrlic SK
AD  - Department of Experimental Pharmacology, Institute for Oncology and Radiology of 
      Serbia, Belgrade, Serbia. zanab@bitsyu.net
FAU - Srdic, T
AU  - Srdic T
FAU - Radulovic, S
AU  - Radulovic S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Cell Cycle/drug effects
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology
MH  - Neoplasms/*drug therapy/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Protein Kinases/*metabolism
MH  - Signal Transduction
MH  - Sirolimus/*analogs & derivatives/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases
RF  - 61
EDAT- 2007/02/20 09:00
MHDA- 2007/03/28 09:00
CRDT- 2007/02/20 09:00
PHST- 2007/02/20 09:00 [pubmed]
PHST- 2007/03/28 09:00 [medline]
PHST- 2007/02/20 09:00 [entrez]
PST - ppublish
SO  - J BUON. 2006 Jul-Sep;11(3):267-76.